Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Perinatal outcomes in 521 gestations after fresh and frozen cycles: a secondary outcome of a randomized controlled trial comparing GnRH antagonist versus GnRH agonist protocols

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The reproductive microbiome - clinical practice recommendations for fertility specialists

    Research output: Contribution to journalReviewResearchpeer-review

  2. Pregnancy outcomes after recurrent pregnancy loss: a longitudinal cohort study on stress and depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum anti-Müllerian hormone concentration before and after salpingectomy for ectopic pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Survival of selected patients with ovarian cancer treated with fertility-sparing surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

RESEARCH QUESTION: Are perinatal outcomes different after treatment with the gonadotrophin-releasing hormone (GnRH) antagonist versus the long GnRH agonist protocol for IVF?

DESIGN: Perinatal outcomes were secondary outcomes in a large Phase IV, dual-centre, open-label, randomized controlled trial to compare GnRH antagonist and long GnRH agonist protocols in women <40 years undergoing their first assisted reproductive technology treatment. Women (n = 1050) were randomized in a ratio 1:1 from January 2009 to December 2013 and followed until December 2016. All fresh and frozen embryo transfer (FET) cycles from a single oocyte aspiration, resulting in a gestation (human chorionic gonadotrophin >10 IU/l) were included (n = 521). Data were analysed to compare preterm birth [PTB] (<37 weeks), very PTB (<32 weeks), low birthweight [LBW] (<2500 g) and very LBW (<1500 g) rates among singleton live births in GnRH antagonist versus agonist protocol.

RESULTS: Similar perinatal outcomes were found after both protocols. In singletons after fresh embryo transfer, mean gestational age at delivery was 39.1 ± 2.49 versus 39.3 ± 1.90 (P = 0.67) and very PTB rates 1.9% versus 0% (P = 0.17). Mean birthweight was 3264 ± 662 g in the antagonist and 3341 ± 562 g in the agonist group (P = 0.37). LBW was found in 12.4% versus 7% (P = 0.19) and very LBW in 2.9% versus 1% (P = 0.34). In FET cycles, the perinatal outcomes were similar. Small for gestational age and large for gestational age rates were similar in both protocols for singleton live births after fresh and FET.

CONCLUSIONS: Perinatal outcomes are similar after the GnRH antagonist versus GnRH agonist protocols for IVF. The choice of the GnRH analogue in ovarian stimulation should be based solely on optimizing the chance of pregnancy and not on risks in perinatal outcomes.

Original languageEnglish
JournalReproductive BioMedicine Online
Volume39
Issue number4
Pages (from-to)659-664
ISSN1472-6483
DOIs
Publication statusPublished - Oct 2019

    Research areas

  • ART, GnRH agonist, GnRH antagonist, Perinatal outcomes

ID: 57796627